Clinical Study on Sensitivity of Oral and Maxillofacial Cancers with Chemotherapy

陈万涛,郭伟,徐骎,周晓健,张萍,羊一飞,邱蔚六

DOI: https://doi.org/10.3781/j.issn.1000-7431.2004.01.021

2004-01-01

Tumor

Abstract:Objective The aim of this study was to evaluate the clinical significance of chemosensitivity testing on tumor cells dissociated from fresh biopsy samples from oral and maxillofacial cancers for individualizing chemotherapy. Methods The chemosensitivity tests of 63 biopsy specimens were performed with modified MTT method. The antitumor drugs in test were cisplatin (CDDP), teniposide (Vm-26), epi-adriamycin(E-ADM), vindesin(VDS), 5-fluorouracil(5-FU), pingyangmycin(PYM), methortrexatum(MTX) and paclitaxel(Taxol). Chemotherapy on the basis of the results of the modified MTT assay was performed on 63 patients and clinical responses to the chemotherapy were evaluated. Results At a drug concenfration of C max×5 the inhibition rates of tumor cells in vitro by the 8 antitumor drugs were recorded respectively,and were compared with the clinical response of chemotherapy. 16 out of 16 patients, whose inhibition rates were more than 50% by the designated drugs, gave a positive clinical response. Twenty two out of 27 patients, whose inhibition rates were more than 30% but less than 50%, gave a positive clinical response. Only 7 of the remains had response. Conclusion The designated antitumor drugs, that give a good clinical chemotherapeutic response, will also produce a higher tumor cell inhibition rate in vitro than those that give a poor chemotherapeutic response (P0.05). Chemo-sensitivity testing by means of modified MTT assay seems to be useful in selecting and in indivedualizing the chemotherapatic agents for patients with oral and maxillofacial cancers.